Huberman Lab
Episode overview

Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Huberman Lab · 4 June 2026 · 5 Egleze moments
Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams ▶

What happened in this episode?

In this Huberman Lab Essentials episode, host Andrew Huberman interviewed Dr. Nolan Williams, a Stanford psychiatrist and neurologist specializing in treatment-resistant depression and brain stimulation technologies. The conversation centered on revolutionary approaches to treating severe depression, particularly Williams' Stanford Neuromodulation Therapy (SNT), which achieves 60-90% remission rates within 1-5 days by compressing 7.5 months of traditional TMS treatment into an intensive protocol. Williams revealed the American Heart Association recently added depression as the fourth major cardiovascular risk factor alongside hypertension, cholesterol, and diabetes, underscoring depression's systemic health impact. The discussion challenged foundational psychiatric assumptions, with Williams explicitly stating the chemical imbalance theory is false and proposing 'Psychiatry 3.0' focused on correctable brain circuits rather than serotonin deficits or irreversible childhood trauma. Williams presented first-in-human ibogaine research with Navy SEALs and special forces veterans, reporting dramatic resolution of moral injury and PTSD symptoms after 24-36 hour sessions described as 'ten years of psychotherapy in a night.' The conversation covered psilocybin trials showing two-thirds clinical improvement in depression, MDMA's efficacy for PTSD with effects lasting years, and a Brazilian prison study demonstrating ayahuasca reduced recidivism rates. Williams emphasized these substances should never be recreational and require strict medical supervision, positioning psychedelic-assisted therapy as a potential breakthrough combining drug effects with psychotherapeutic processing. Throughout, he stressed the importance of rigorous clinical trials and treating depression as a fixable electrophysiological problem rather than permanent deficiency.

What are the key points?

Which topics are covered?

How is this page sourced?

Programme
Huberman Lab
Published
4 June 2026
Original episode
Open the original source ↗

Egleze verifies the speaker, source and timestamp for each linked moment. Unless a moment is explicitly marked independently verified, statements remain attributed claims by the named speaker rather than established facts.

Watch original episode More from Huberman Lab

5 moments from this episode

Source-linked · editorially selected
01
Health, Longevity & Biohacking

American Heart Association Adds Depression as Fourth Major Risk Factor for Heart Disease

at 1:14 · Attributed speaker claim
Recently, the American Heart Association added depression as the fourth major risk factor for coronary artery disease, right? So alongside the risk factors that we know: hypertension, high blood pressure, hyperlipidemia, high cholesterol, and diabetes, you know, high blood sugar. Those three have been on the list for a long time, and depression ended up, you know, being added to the list as the fourth one.

Dr. Williams reported that depression now joins hypertension, high cholesterol, and diabetes as a recognized major cardiovascular risk factor. His lab's research demonstrates direct brain-heart connections, showing that transcranial magnetic stimulation over mood regulatory regions can decelerate heart rate, revealing measurable physiological links between depression and cardiac outcomes.

02
Health, Longevity & Biohacking

Psychiatrist Declares Chemical Imbalance Theory of Depression Wrong, Proposes Circuit-Based Model

at 8:59 · Attributed speaker claim
There's not a deficit of serotonin. You're not born with what people call a chemical imbalance. And psychiatry has known this. This is not actually new information to anybody.

Dr. Williams explicitly rejected the chemical imbalance theory underlying decades of SSRI prescription, stating psychiatry has long known this model was false. He proposed 'Psychiatry 3.0' focused on brain circuitry rather than missing chemicals or childhood trauma, arguing TMS works without altering serotonin levels, demonstrating depression is a fixable electrophysiological circuit problem rather than a permanent deficiency.

03
Health, Longevity & Biohacking

First Human Study Shows Ibogaine Induces Forgiveness of Moral Injury in Special Forces Veterans

at 24:34 · Attributed speaker claim
They come back and say that they've forgiven themselves, which is huge, right? And part of that is being able to see themself in a different light and having empathy finally for themself and being able to kind of have that experience of forgiving.

Dr. Williams revealed results from the first comprehensive neurobiological study of ibogaine in humans, conducted with Navy SEALs and Army Rangers suffering from PTSD and moral injury. The psychedelic session lasts 24-36 hours and is described as 'ten years of psychotherapy in a night.' Veterans reported forgiving themselves for traumatic wartime incidents, though full data analysis is pending.

04
Crime & Justice

Brazilian Prison Study Shows Ayahuasca Reduced Recidivism Rates Compared to Control Group

at 30:57 · Attributed speaker claim
The recidivism rate or the return to prison rate in the ayahuasca-exposed individuals was statistically significantly lower than the recidivism rate in the control group, suggesting that, you know, whatever is going on there seems to have an effect on whatever drives criminal behavior.

Dr. Williams described Brazilian research in which prisoners who received ayahuasca sessions showed statistically lower rates of returning to prison compared to control groups. The study utilized ayahuasca's status as a Catholic sacrament in some Brazilian sects, though Williams cautioned against interpreting this as a recommendation for widespread prison psychedelic use.

05
Health, Longevity & Biohacking

Stanford Psychiatrist Reports TMS Depression Treatment Achieves 60-90% Remission in Five Days

at 34:22 · Attributed speaker claim
What we've found is that folks will, within 1 to 5 days, in more cases than not, and depending upon if you're looking at this open label or in trials, somewhere between 60 and 90% of the time, they will go into full-on remission in the sense they're totally normal from a mood standpoint at the end of this.

Dr. Nolan Williams described Stanford's accelerated TMS protocol, which compresses 7.5 months of traditional treatment into 5 days using spaced learning theory. Patients receive 90 minutes of magnetic brain stimulation spread across 10 hours daily for 5 consecutive days, targeting the dorsolateral prefrontal cortex. Some patients have maintained remission for up to 4 years, though durability remains variable.